

A digital hereditary risk assessment tool efficiently identifies patients in need of genetic evaluation Jenna Petersen, Andi Hila, Kiley Johnson, Ashley Daley, Colleen Caleshu; Genome Medical

BACKGROUND

Scalable approaches to identifying patients who have a hereditary risk for cancer are needed.

RISE Risk Assessment Module: Hereditary Cancer is a patient-administered digital tool that has been clinically validated to identify individuals who may benefit from cancer genetic testing.

AIM

To evaluate the usability and yield of this hereditary cancer risk assessment tool in ob/gyn clinics.

METHODS

Retrospective chart review of patients who interacted with the tool in ob/gyn clinics.

RESULTS

July 2021 - April 2022


1608 Patients interacted with the tool

Mean age



A patient-administered digital tool is efficient, usable, and effective at identifying patients who need genetic testing for hereditary cancer risk.

95.3% of patients who started the tool completed it.



22.7% (348/1532) of patients met criteria for genetic testing.

Only 8.3% (29/348) of patients who met criteria had a personal history of cancer.

<u>CLICK HERE</u> to view:

- Our other poster on this topic
- To find out when you can talk with the authors

USABILITY

95.3% (1532/1608) of patients who started the tool completed it



3.8 minutes

mean time to complete the tool

84% of patients completed the tool in under 6 minutes.

CRITERIA MET

Patients met a mean of 1.8 testing criteria (SD 1.5) per patient

Most patients met criteria based on a single criterion (59.5%, 207/348)

The majority of patients met criteria through only the breast/ovarian/pancreatic cancer criteria, colorectal criteria, or both.

